Global Combined Hormonal Contraceptives (CHC) Market Revenue,Share ,Growth ,Size Analysis & Forecast to 2019

Scope of the Report
The report titled “Global Combined Hormonal Contraceptive (CHC) Market: Trends and Opportunities (2014-2019)” provides an in-depth analysis of the global CHC market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses key opportunities in the market and outlines the factors that are and will be driving growth of the industry. Growth of the overall CHC industry has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. An insight into strategic issues affecting key brands on the market is provided followed by an analysis of the leading companies in the hormonal contraceptives market. The report also analyzes the key CHC products in pipeline.Further, key players of the industry like Agile Therapeutics; Bayer Healthcare; Teva Pharmaceuticals and Actavis PLC; are analyzed in the report.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/185253 .

Country Coverage
United states
United Kingdom
India
China
Japan

Company Coverage
Agile Therapeutics Inc.
Actavis Plc.
Bayer Healthcare
Teva Pharmaceuticals

Executive Summary
Combined Hormonal Contraceptives (CHC) is widely being used as an effective and reversible birth control method. Mainly used for preventing pregnancies but sometimes also used for treating acne vulgaris, endometriosis, polycystic ovarian syndrome and irregular menstrual flow, CHC works by preventing ovulation i.e. release of egg from ovaries. The hormones are provided in the combined pill, patch or ring.

Purchase a copy of Global Combined Hormonal Contraceptives (CHC) Market visit @ http://www.orbisresearch.com/contact/purchase/185253 For more information contact sales@orbisresearch.com .

Most popular Combined Hormonal Contraceptives products are Nuvaring and Ortho Evra. CHC products are broadly used throughout the world by women in the age-group of 15 to 49 years. With increasing health consciousness and awareness, adoption of CHC products or birth control methods is increasing in lesser privileged economic segments too. The growth of CHC market is driven by urbanization and increasing user awareness, rise in menstruating population globally and initiatives taken by governments to encourage the use of contraception. Major trends prevailing in the market are the increasing number of mergers and acquisitions in this business space and demand for reversible method of contraception with fewer side effects

Browse Complete Report @
http://www.orbisresearch.com/reports/index/global-combined-hormonal-contraceptives-chc-market-trends-and-opportunities-2014-19 .

Some points from TOC:
1. Executive Summary

2. Combined Hormonal Contraceptives Market: An Overview
2.1 Definition
2.2 History
2.3 Classification
2.3.1 Combined Oral Contraceptive Pills
2.3.2 Combined Vaginal Rings
2.3.3 Combined Transdermal Patches
2.3.4 Combined Injectable Birth Control
2.3.5 Combined Emergency Contraceptive Pills
2.4 Mechanism of Action
2.5 Components of CHCs
2.6 Advantages of Combined Hormonal Contraceptives
2.7 Disadvantages of Combined Hormonal Contraceptives
2.8 Contraindications
2.9 Serious Risks

For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research
Follow us on Twitter: https://twitter.com/orbisresearch
Like us on Facebook: https://www.facebook.com/pages/Orbis-Research/820969017982115

This release was published on openPR.